Handelsbanken Fonder’s BioMarin Pharmaceuticals BMRN Stock Holding History

Handelsbanken Fonder’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.59M	Buy	62,700 +4,200	+7%	+$230K	0.01%	603
2026 Q1	$3.31M	Hold	58,500	–	–	0.01%	579
2025 Q4	$3.48M	Buy	58,500 +5,600	+11%	+$305K	0.01%	573
2025 Q3	$2.87M	Buy	52,900 +3,100	+6%	+$177K	0.01%	616
2025 Q2	$2.74M	Sell	49,800 -7,700	-13%	-$453K	0.01%	554
2025 Q1	$4.07M	Buy	57,500 +8,600	+18%	+$579K	0.02%	456
2024 Q4	$3.21M	Sell	48,900 -75,122	-61%	-$5.03M	0.01%	531
2024 Q3	$8.72M	Buy	124,022 +2,456	+2%	+$205K	0.03%	368
2024 Q2	$10M	Buy	121,566 +24,754	+26%	+$2.06M	0.04%	337
2024 Q1	$8.46M	Buy	96,812 +6,762	+8%	+$605K	0.04%	379
2023 Q4	$8.68M	Sell	90,050 -1,705	-2%	-$151K	0.04%	362
2023 Q3	$8.12M	Buy	91,755 +1,593	+2%	+$142K	0.05%	346
2023 Q2	$7.82M	Buy	90,162 +12,451	+16%	+$1.17M	0.04%	365
2023 Q1	$7.56M	Buy	77,711 +2,408	+3%	+$250K	0.04%	361
2022 Q4	$7.79M	Buy	75,303 +5,044	+7%	+$474K	0.05%	358
2022 Q3	$5.96M	Hold	70,259	–	–	0.04%	378
2022 Q2	$5.82M	Sell	70,259 -232,242	-77%	-$18.5M	0.04%	403
2022 Q1	$23.3M	Sell	302,501 -3,850	-1%	-$322K	0.13%	168
2021 Q4	$27.1M	Buy	306,351 +85,338	+39%	+$7.04M	0.13%	171
2021 Q3	$17.1M	Buy	221,013 +4,443	+2%	+$351K	0.09%	230
2021 Q2	$18.1M	Buy	216,570 +173,799	+406%	+$13.8M	0.09%	229
2021 Q1	$3.23M	Sell	42,771 -420	-1%	-$34.3K	0.02%	525
2020 Q4	$3.79M	Sell	43,191 -98	-0.2%	-$7.77K	0.02%	470
2020 Q3	$3.29M	Buy	43,289 +1,600	+4%	+$162K	0.02%	443
2020 Q2	$5.14M	Buy	+41,689	New	+$4.14M	0.04%	336
2016 Q4	–	Sell	-16,500	Closed	-$1.53M	–	161
2016 Q3	$1.53M	Hold	16,500	–	–	0.04%	141
2016 Q2	$1.28M	Sell	16,500 -5,000	-23%	-$425K	0.05%	119
2016 Q1	$1.77M	Sell	21,500 -17,989	-46%	-$1.46M	0.08%	117
2015 Q4	$4.14M	Buy	+39,489	New	+$4.12M	0.08%	215

Other funds holding BMRN

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

AIM

ARGA Investment Management Stamford, Connecticut $3.92B AUM 35.93% 1-Year Est. Return

FWIA

Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

SAM

SEB Asset Management Stockholm $26.6B AUM

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

EIP

Easterly Investment Partners Beverly, Massachusetts $1.97B AUM 25.87% 1-Year Est. Return

Handelsbanken Fonder's BMRN Position: Q2 2026 in Review

Handelsbanken Fonder increased its BioMarin Pharmaceuticals (BMRN) stake by 7.2% in Q2 2026, buying an estimated $230K and bringing the position to 62,700 shares worth $3.59M. The position accounts for 0.01% of the portfolio, ranked #603.

Handelsbanken Fonder first reported a position in BMRN in Q4 2015 and has held it in 29 quarters since. The position peaked at $27.1M in Q4 2021. 193 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Handelsbanken Fonder held 62,700 shares of BioMarin Pharmaceuticals worth $3.59M as of Q2 2026.
Handelsbanken Fonder bought 4,200 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $230K.
BioMarin Pharmaceuticals made up 0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #603 holding.
Handelsbanken Fonder first reported a position in BioMarin Pharmaceuticals in Q4 2015 and has held it in 29 quarters since.
Handelsbanken Fonder's BioMarin Pharmaceuticals position peaked at $27.1M in Q4 2021.
193 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.